The UK and US have agreed to a significant commercial pact that will keep zero duties on British drug exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost spending on drugs through the National Health Service (NHS). This move secures that tariffs on these key exports will be held at nothing for a period of three years.
This agreement is in response to earlier statements to dramatically increase tariffs on branded drug imports, with figures floated up to double the cost.
"This agreement between the United Kingdom strengthens the global environment for innovative medicines and introduces long-overdue equity to U.S.–U.K. drug exports," a statement noted.
Trade Importance
Drugs constitute one of the Britain's biggest goods shipped to the US, which is easily the largest destination for leading UK drugmakers.
Statistics indicate that in the year prior to September, the UK exported drugs valued at £11.1bn to the US. This figure represented 17.4% of British export trade in that span.
"This agreement secures work, increases investment and paves the way for the UK to become a international leader for biotech and pharma," a minister stated.
Key UK Commitments
The agreement includes several notable changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to prevent overspending will be capped at 15%. Previously, repayments topped twenty percent.
Recent Tensions
The pact comes amid a protracted dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
These tensions were heightened by arguments that American patients were paying significantly more for the same drugs than patients in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
